Extended Data Fig. 1: Characterization of ILC3s in the CNS.
From: Antigen-presenting innate lymphoid cells orchestrate neuroinflammation
a, Representative time course and clinical disease categorization of active EAE (n = 4, 5 mice/timepoint). b-c, Quantification of ILC3 frequency and absolute counts within indicated tissues at steady state (Naive) (n = 6 mice) versus EAE onset (d11, n = 7), acute (d15, n = 8) or chronic (d20, n = 9) phase (b) and reverse flow cytometry gating strategy defining all GFP+ cells in the CNS (d15) (n = 4 mice/group) (c) during EAE in Rorc-eGFP mice. d-e, Naive C57BL/6 mice (n = 4 mice/group) were immunized with either PBS (Naive), CFA/PTx alone, or with CFA/PTx/MOGp. At day 15 post-immunization, ILC3s in the CNS, inLN and cLN were enumerated by flow cytometry: d, Representative flow cytometry gating strategy for ILC3s in CNS (Lin1 = CD3, CD5, CD8, Lin2 = CD11b, CD11c, B220), e, Quantitation of frequencies and absolute counts of ILC3s. f-g, Representative flow cytometry on YFP+ ILCs (f) and quantification of differential expression of ILC heterogeneity in YFP+/- ILCs (g) in the CNS of Rorc-creeYFP mice during active EAE (n = 6 mice/group) (Lin 1 = B220, CD11b, CD11c, Lin 2 = CD3ε, CD5, CD8, Ly6C). Data in a-f are representative of two independent experiments with similar results and data in b are pooled from two independent experiments. Results are shown as mean ± s.d. Statistics are calculated by one-way (b, e) analysis of variance (ANOVA) with Sidak’s multiple comparisons test.
